Napro Biotherapeutics (NASDAQ:NPRO)
Historical Stock Chart
From Jul 2019 to Jul 2024
![Click Here for more Napro Biotherapeutics Charts. Click Here for more Napro Biotherapeutics Charts.](/p.php?pid=staticchart&s=N%5ENPRO&p=8&t=15)
NaPro Announces Additions to Scientific Advisory Board
BOULDER, Colo., Jan. 12 /PRNewswire-FirstCall/ -- NaPro BioTherapeutics, Inc.
today announced the following new appointments to its Scientific Advisory
Board:
Paul A Bunn, Jr., M.D.: Dr. Bunn is currently the Director of the University of
Colorado Cancer Center, past president (2002-2003) of the American Society of
Clinical Oncology (ASCO), and former chairman of the Oncology Drugs Advisory
Committee (ODAC). Dr. Bunn is an authority in the field of clinical oncology
with a research specialty in lung cancer. Dr. Bunn received his M.D. from
Cornell University Medical Center.
Theodore Friedmann, M.D.: Dr. Friedmann is a Professor of Pediatrics and
Director of the Gene Therapy Program at the University of California, San Diego.
Since 2000, he has served as the Chairman of the Recombinant DNA Advisory
Committee (RAC) at the National Institutes of Health. Dr. Friedmann has over 40
years of research experience in the areas of genetics and molecular therapies.
He received his M.D. from the University of Pennsylvania.
Susan J. Gross, M.D.: Dr. Gross is the Co-Director of the Division of
Reproductive Genetics at Montefiore Medical Center and Albert Einstein College
of Medicine and an associate professor in Obstetrics, Gynecology and Pediatrics.
Dr. Gross performs research and provides genetic counseling for women with
hereditary cancer and those at high risk for genetic birth defects. She is board
certified in obstetrics and gynecology and medical genetics. Dr. Gross received
her M.D. from the University of Toronto.
Stephen S. Morse, Ph.D.: Dr. Morse is Director of the Center for Public Health
and Associate Professor of Clinical Epidemiology at Columbia University's
Mailman School of Public Health. He is an expert in the epidemiology of
emerging infections, international cooperation for infectious disease
surveillance, and defense against bioterrorism. Dr. Morse spent four years in
government service as Program Manager at the Defense Advanced Research Projects
Agency (DARPA), Department of Defense, where he co-directed the Pathogen
Countermeasures program and subsequently directed the Advanced Diagnostics
program there. He holds a Ph.D. in Virology from the University of Wisconsin.
"We are pleased to welcome these eminent scientists to our Scientific Advisory
Board," stated Robert E. Pollack, Ph.D., Chairman of the NaPro Scientific
Advisory Board. "These distinguished experts will expand the Board's collective
expertise in NaPro's core research and development areas and help us guide the
Company's strategy to bring forward promising new therapies in the field of
oncology and the treatment of hereditary disease."
Other members of NaPro's Scientific Advisory Board are:
Robert E Pollack, Ph.D. (Chairman) Professor of Biological Sciences & Director,
Center for the Study of Science and Religion, Columbia University
Anthony J. Lechich, M.D., Senior Vice President of Medical Affairs and Medical
Director, Terence Cardinal Cooke Health Care Center
Malcolm A. S. Moore, D. Phil., Enid A Haupt Professor of Cell Biology & Head,
James Ewing Laboratory of Developmental Hematopoiesis, Memorial Sloan-Kettering
Cancer Center
Seth A. Rudnick, M.D., Managing Partner, Canaan Partners LLP
Ethan Signer, Ph.D., Executive Director, High Q Foundation, Professor of Biology
Emeritus, Massachusetts Institute of Technology
Nancy S. Wexler, Ph.D., Higgins Professor of Neuropsychology, Columbia
University
About NaPro BioTherapeutics
NaPro BioTherapeutics, Inc. is a life science company focused on the development
of therapies for the targeted treatment of cancer and hereditary disease.
For more information about NaPro and its technologies, visit NaPro's web site at
http://www.naprobio.com/ .
Forward Looking Statements
The statements in this news release that are not historical facts are
forward-looking statements that represent management's beliefs and assumptions
as of the date of this news release, based on currently available information.
Forward-looking statements can be identified by the use of words such as
"believes," "intends," "estimates," "may," "will," "should," "anticipated,"
"expected" or comparable terminology or by discussions of strategy. Although
the Company believes that the expectations reflected in such forward-looking
statements are reasonable, it cannot assure that these expectations will prove
to be correct. Such statements involve risks and uncertainties including: risks
associated with development of therapies in the field of oncology and the
treatment of hereditary disease, and all of those factors identified under the
captions "Risk Factors," "Special Note Regarding Forward Looking Statements" or
"Cautionary Note Regarding Forward Looking Statements" in the Company's
documents filed from time to time with the SEC, including the Company's
registration statement on Form S-3, as amended, dated August 8, 2003, its Annual
Report on Forms 10-K and 10-K/A for the year ending December 31, 2002 filed with
the SEC on March 27, April 30, August 8 and October 24, 2003, and its Quarterly
Report on Form 10-Q for the quarter ended October 1, 2003 filed with the
Securities and Exchange Commission on November 14, 2003. Should one or more of
these risks materialize (or the consequences of such a development worsen), or
should the underlying assumptions prove incorrect, actual results could differ
materially from those forecasted or expected. The Company disclaims any
intention or obligation to update publicly or revise such statements whether as
a result of new information, future events or otherwise.
For further information, please contact L. Robert Cohen, Vice President,
Investor Relations of NaPro BioTherapeutics, Inc., +1-212-218-8715.
DATASOURCE: NaPro BioTherapeutics, Inc.
CONTACT: L. Robert Cohen, Vice President, Investor Relations of NaPro
BioTherapeutics, Inc., +1-212-218-8715; or investors, Lilian Stern of Stern
Investor Relations, +1-212-362-1200; or media, Peter Steinerman,
+1-516-374-3031, both for NaPro BioTherapeutics, Inc.
Web site: http://www.naprobio.com/